Letter to the Editor
Split Viewer
Blood Res 2013; 48(1):
Published online March 31, 2013
https://doi.org/10.5045/br.2013.48.1.68
© The Korean Society of Hematology
Ruxolitinib changes the natural course of myelofibrosis and its transplant outcome
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Correspondence to : Chul Won Jung. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. Tel: +82-2-3410-3452, leukemia1@skku.edu
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
REFERENCES
- Verstovsek, S, Mesa, RA, Gotlib, J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 2012;366;799-807.
- Vannucchi, AM, Passamonti, F, Al-Ali, HK, et al. Reductions in JAK2 V617F allele burden with ruxolitinib treatment in comfort-II, a phase 3 study comparing the safety and efficacy of ruxolitinib with best available therapy (BAT). Blood, 2012;120;634(abst 802)
- Verstovsek, S, Kantarjian, HM, Estrov, Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood, 2012;120;1202-1209.
- Carniti, C, Gimondi, S, Vaccaroli, R, et al. Inhibition of JAK1/JAK2 is more effective than inhibition of JAK3 in protecting mice from acute graft-versus-host disease (aGVHD) by significantly decreasing alloreactive CD4+ T-cells. Blood, 2012;120;702(abst 2997)
- Ciurea, SO, Sadegi, B, Wilbur, A, et al. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol, 2008;141;80-83.
PDF
Standard view
Export citation
Share Article
Letter to the Editor
Blood Res 2013; 48(1): 68-69
Published online March 31, 2013 https://doi.org/10.5045/br.2013.48.1.68
Copyright © The Korean Society of Hematology.
Ruxolitinib changes the natural course of myelofibrosis and its transplant outcome
Chul Won Jung, M.D.*
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Correspondence to: Chul Won Jung. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. Tel: +82-2-3410-3452, leukemia1@skku.edu
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
- Verstovsek, S, Mesa, RA, Gotlib, J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 2012;366;799-807.
- Vannucchi, AM, Passamonti, F, Al-Ali, HK, et al. Reductions in JAK2 V617F allele burden with ruxolitinib treatment in comfort-II, a phase 3 study comparing the safety and efficacy of ruxolitinib with best available therapy (BAT). Blood, 2012;120;634(abst 802)
- Verstovsek, S, Kantarjian, HM, Estrov, Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood, 2012;120;1202-1209.
- Carniti, C, Gimondi, S, Vaccaroli, R, et al. Inhibition of JAK1/JAK2 is more effective than inhibition of JAK3 in protecting mice from acute graft-versus-host disease (aGVHD) by significantly decreasing alloreactive CD4+ T-cells. Blood, 2012;120;702(abst 2997)
- Ciurea, SO, Sadegi, B, Wilbur, A, et al. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol, 2008;141;80-83.
Previous Article
